Related Experiment Video
Updated: May 12, 2026

Targeting Biofilm Associated Staphylococcus aureus Using Resazurin Based Drug-susceptibility Assay
Published on: May 5, 2016
Targeting biofilm-driven antibiotic resistance: emerging mechanisms and next-generation therapeutic interventions
Abdulkarim Mbaraka1, Ritu Raj Meena2, Ekta Menghani2
1Department of Biochemistry and Molecular Biology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.
Abstract:
Biofilm mediated antimicrobial resistance (AMR) has become a critical global health and economic challenge, affecting both community and healthcare settings. Microbial Biofilms significantly enhance the antibiotic tolerance and cause the persistent and device-associated infections via limited drug penetration, degradation of antibiotics, and assist horizontal gene transfer. Biofilm-mediated antimicrobial resistance remains a major obstacle to treating infectious diseases today. Biofilms can boost antibiotic tolerance by up to 1,000 times and lead to chronic, persistent, and device-associated infections. The lack of FDA-approved anti-biofilm drugs highlights the urgent need for new therapeutic strategies and mechanistic insights. Redefining the treatment landscape and improving outcomes for resistant infections could be achieved through a multi-platform therapeutic approach. This review summarizes recent developments in our knowledge of how biofilms contribute to antibiotic resistance and highlights new therapeutic strategies, such as nanotechnology, antimicrobial peptides, bacteriophage-derived enzymes, quorum-sensing inhibitors, CRISPR-based tools, microbiome engineering, and AI-driven drug discovery.
Insights
Antimicrobial resistance (AMR) driven by microbial biofilms is a major health challenge. New strategies like nanotechnology and AI are emerging to combat these persistent infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Discovery
Background:
- Biofilm-mediated antimicrobial resistance (AMR) poses a significant global health and economic threat.
- Microbial biofilms increase antibiotic tolerance by up to 1,000 times, leading to persistent and device-associated infections.
- Current treatment options are limited by the lack of FDA-approved anti-biofilm drugs.
Purpose of the Study:
- To review recent advancements in understanding biofilm-mediated AMR.
- To highlight novel therapeutic strategies for combating biofilm infections.
- To emphasize the need for multi-platform approaches to redefine treatment for resistant infections.
Main Methods:
- Literature review of recent developments in biofilm research.
- Analysis of emerging anti-biofilm therapeutic strategies.
- Synthesis of knowledge on biofilm mechanisms contributing to antibiotic resistance.
Main Results:
- Biofilms contribute to AMR through mechanisms like limited drug penetration, antibiotic degradation, and enhanced horizontal gene transfer.
- Several promising therapeutic strategies are emerging, including nanotechnology, antimicrobial peptides, and AI-driven drug discovery.
- A multi-platform therapeutic approach is crucial for improving outcomes against resistant infections.
Conclusions:
- Understanding biofilm mechanisms is key to developing effective anti-biofilm therapies.
- Novel strategies offer potential solutions to overcome the challenge of biofilm-mediated AMR.
- Continued research and development of multi-modal treatments are essential for tackling this critical global health issue.
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Biofilms
Clinical Significance of Antibiotic Resistance
Development of Antibiotic Resistance
Gene Regulation in Microbial Communities: Quorum Sensing
Biological Methods for Microbial Control
